Table 1: Subject Characteristics.

Clinical characteristics of the main cohort of HepBlock9 study subjects (n = 160).

Age – mean (SD)	62.1 (10.2)
Sex – no. (%)
Male	111 (69.4)
Female	46 (28.8)
Nonbinary	3 (1.8)
Race – no. (%)
White	41 (25.6)
Black or African American	35 (21.9)
Asian	45 (28.1)
American Indian or Alaskan Native	2 (1.3)
Native Hawaiian or other Pacific Islander	5 (3.1)
Multiple races	8 (5.0)
Other/Unknown	40 (25.0)
Hispanic Ethnicity – no. (%)	40 (25.0)
Obstructive Coronary Artery Disease – no. (%)	64 (40)
Any Atherosclerosis – no. (%)	118 (73.8)
Acute Coronary Syndrome – no. (%)	8 (5.0)
Percutaneous Coronary Intervention Performed – no. (%)	9 (5.6)
Statin – no. (%)	112 (70.0)
Lipid Profile (in mg/dl) – mean/median (SD)
Total Cholesterol (n = 149)	161/158 (47.6)
Non-HDL Cholesterol (n = 149)	117/110 (43.9)
≥ 130 – no. (% of 149)	45 (30.2)
LDL Cholesterol (n = 144)	89.7/81.5 (38.3)
HDL Cholesterol (n = 149)	44.3/44.0 (13.7)
Triglycerides (n = 146)	140/118 (84.9)
Creatinine (in mg/dl) – mean (SD)	1.23 (1.81)
≥1 – no. (%)	78 (48.8)
Heparin Dose (in Units) – mean (SD)	5220 (1780)
≥5000 – no. (%)	96 (60.0)